Cara Therapeutics, Inc.
Index- P/E- EPS (ttm)-1.25 Insider Own1.20% Shs Outstand53.62M Perf Week8.21%
Market Cap509.83M Forward P/E- EPS next Y-0.23 Insider Trans-4.37% Shs Float45.02M Perf Month-6.07%
Income-66.40M PEG- EPS next Q-0.23 Inst Own67.10% Short Float15.84% Perf Quarter2.42%
Sales48.90M P/S10.43 EPS this Y28.70% Inst Trans9.88% Short Ratio17.50 Perf Half Y-22.80%
Book/sh3.81 P/B2.56 EPS next Y81.50% ROA-28.80% Target Price25.00 Perf Year-31.29%
Cash/sh3.01 P/C3.24 EPS next 5Y- ROE-31.50% 52W Range7.40 - 18.93 Perf YTD-19.95%
Dividend- P/FCF- EPS past 5Y3.60% ROI-39.20% 52W High-48.49% Beta0.96
Dividend %- Quick Ratio8.20 Sales past 5Y205.90% Gross Margin95.70% 52W Low31.76% ATR0.53
Employees84 Current Ratio8.30 Sales Q/Q- Oper. Margin- RSI (14)50.86 Volatility6.55% 5.37%
OptionableYes Debt/Eq0.00 EPS Q/Q87.20% Profit Margin- Rel Volume0.74 Prev Close9.40
ShortableYes LT Debt/Eq0.00 EarningsAug 08 AMC Payout- Avg Volume407.52K Price9.75
Recom1.70 SMA200.73% SMA50-4.61% SMA200-7.00% Volume303,492 Change3.72%
Mar-08-22Upgrade JP Morgan Neutral → Overweight $17 → $20
Nov-01-21Resumed Canaccord Genuity Buy $33
Aug-03-21Initiated JP Morgan Neutral $16
Apr-21-20Reiterated H.C. Wainwright Buy $30 → $33
Aug-12-19Reiterated H.C. Wainwright Buy $31 → $30
May-29-19Reiterated Laidlaw Buy $26 → $32
Feb-06-19Resumed Jefferies Buy $22
Jan-15-19Initiated BofA/Merrill Neutral $19
Sep-21-18Initiated Cantor Fitzgerald Overweight
Sep-13-18Initiated Jefferies Buy $30
Aug-08-18Reiterated Stifel Buy $22 → $26
Jun-28-18Reiterated H.C. Wainwright Buy $24 → $26
Mar-12-18Resumed H.C. Wainwright Buy $22
Feb-12-18Upgrade Janney Neutral → Buy
Jan-19-18Initiated Seaport Global Securities Buy $27
Jun-30-17Reiterated Stifel Buy $24 → $20
Jun-30-17Reiterated Laidlaw Buy $35 → $30
Jun-30-17Downgrade Janney Buy → Neutral
Mar-28-17Reiterated Laidlaw Buy $20 → $35
Mar-28-17Reiterated H.C. Wainwright Buy $22 → $30
Sep-28-22 07:00AM
Sep-20-22 09:47AM
Sep-12-22 07:00AM
Sep-08-22 02:27PM
07:00AM Loading…
Sep-06-22 07:00AM
Aug-24-22 07:00AM
Aug-22-22 07:00AM
Aug-19-22 01:00AM
Aug-08-22 05:15PM
Aug-04-22 08:48AM
Aug-03-22 07:00AM
Aug-01-22 04:01PM
Jul-28-22 09:14AM
06:39AM Loading…
Jul-22-22 06:39AM
Jun-30-22 10:19AM
Jun-06-22 11:46AM
May-23-22 07:04AM
May-17-22 07:00AM
May-09-22 05:25PM
May-04-22 09:05AM
May-03-22 04:01PM
Apr-29-22 07:00AM
Apr-28-22 01:00AM
Apr-13-22 11:17AM
Apr-05-22 07:00AM
04:01PM Loading…
Apr-04-22 04:01PM
Mar-28-22 12:13PM
Mar-08-22 04:01PM
Mar-01-22 05:15PM
Feb-25-22 07:15AM
Feb-22-22 04:01PM
Feb-18-22 07:00AM
Feb-17-22 03:03PM
Feb-15-22 11:19AM
Feb-14-22 10:29AM
Feb-12-22 06:45AM
Feb-10-22 05:35PM
Feb-08-22 08:05AM
Feb-04-22 08:05AM
Jan-28-22 12:48PM
Jan-25-22 12:45PM
Jan-10-22 08:00AM
Jan-03-22 04:01PM
Dec-20-21 07:00AM
Dec-14-21 05:10AM
Nov-18-21 08:30AM
Nov-17-21 12:01PM
Nov-09-21 04:30PM
Nov-08-21 08:30PM
Nov-03-21 08:00AM
Nov-01-21 04:15PM
Oct-26-21 10:18AM
Oct-15-21 06:59AM
Oct-04-21 07:00AM
Sep-29-21 07:00AM
Sep-24-21 07:00AM
Sep-20-21 04:26PM
Sep-04-21 08:55AM
Aug-27-21 05:33PM
Aug-24-21 04:08PM
Aug-23-21 07:06PM
Aug-15-21 08:07AM
Aug-11-21 10:22AM
Aug-09-21 09:00PM
Aug-04-21 07:04PM
Aug-02-21 04:01PM
Jul-29-21 03:53PM
Jul-12-21 10:26AM
Jun-11-21 07:30AM
Jun-10-21 02:02AM
May-29-21 06:41AM
May-25-21 07:00AM
May-23-21 06:30AM
May-10-21 08:30PM
Cara Therapeutics, Inc., an early commercial-stage biopharmaceutical company, focuses on developing and commercializing chemical entities with a primary focus on pruritus and pain by selectively targeting kappa opioid receptors in the United States. The company is developing product candidates that target the body's peripheral nervous system and immune cells. The company's lead product is KORSUVA (difelikefalin) injection for the treatment of moderate-to-severe pruritus associated with chronic kidney disease (CKD) in adults undergoing hemodialysis. Its product candidate includes Oral KORSUVA (difelikefalin), which has completed Phase II clinical trial to treat pruritus atopic dermatitis and pruritus non-dialysis-dependent chronic kidney disease (NDD-CKD) associated pruritus; and in Phase II clinical trial to treat pruritus chronic liver disease (CLD) primary biliary cholangitis (PBC) and notalgia paresthetica. The company has license agreements with Maruishi Pharmaceutical Co., Ltd to develop, manufacture, and commercialize drug products containing difelikefalin for acute pain and uremic pruritus in Japan; and Chong Kun Dang Pharmaceutical Corporation to develop, manufacture, and commercialize drug products containing difelikefalin in South Korea. Cara Therapeutics, Inc. was incorporated in 2004 and is based in Stamford, Connecticut.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
VOGELBAUM MARTINDirectorSep 14Sale10.2810,800111,02444,988Sep 16 04:21 PM
Ives Jeffrey L.DirectorJul 15Sale9.053,60032,58015,476Jul 19 05:16 PM
BAINS HARRISON M JRDirectorJul 15Sale9.057,20065,16025,076Jul 19 05:13 PM
Posner ChristopherPresident and CEOApr 04Sale12.672,00625,416201,031Apr 05 05:48 PM
Terrillion ScottSec'y; Chief Compliance & G.C.Apr 01Sale11.911,64219,556102,344Apr 05 05:51 PM
Goncalves JoanaChief Medical OfficerApr 01Sale11.911,64219,55674,893Apr 05 05:50 PM
Menzaghi Frederique Ph.D.Chief Scientific Off,SVP-R&DApr 01Sale11.911,78421,247169,781Apr 05 05:49 PM
Reilly Thomas CharlesChief Financial OfficerMar 03Sale11.382,04423,26137,811Mar 04 05:54 PM
Terrillion ScottSec'y; Chief Compliance & G.C.Mar 03Sale11.381,78720,336103,986Mar 04 05:51 PM
Goncalves JoanaChief Medical OfficerFeb 25Sale10.291,97220,29276,535Mar 01 04:14 PM
Terrillion ScottSec'y; Chief Compliance & G.C.Feb 25Sale10.291,97220,292100,440Mar 01 04:19 PM
Ives Jeffrey L.DirectorNov 12Sale16.048,180131,2077,200Nov 16 06:15 PM
Goncalves JoanaChief Medical OfficerNov 01Sale17.151,00017,15045,900Nov 03 04:55 PM
Goncalves JoanaChief Medical OfficerOct 27Sale15.001,00015,00046,900Oct 28 06:34 PM